Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
Fulvestrant 3-
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "Fulvestrant 3-" in MCE Product Catalog:
Cat. No.: HY-13636S
Purity: 97.47%
Synonyms: ICI 182780-d3; ZD 9238-d3; ZM 182780-d3
Target:
Research Areas:
Fulvestrant 3-β-D-Glucuronide, a metabolite, is glucuronide and sulfate conjugates of Fulvestrant (HY-13636), a pure anti-estrogenic steroid. Fulvestrant 3-β-D-Glucuronide can be used for the research of breast cancer .
Cat. No.: HY-137144
CAS No.: 1853279-29-4
Synonyms: ZB716
Target:
Research Areas:
Fulvestrant-3-boronic acid is an orally active ERα inhibitor, which binds to ERα competitively (IC50 = 4.1 nM) and effectively degrades ERα in breast cancer cells .
Cat. No.: HY-13636A
CAS No.: 1316849-17-8
Synonyms: ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)
Research Areas:
Fulvestrant (ICI 182780; ZD 9238) S enantiomer is the S-enantiomer of Fulvestrant (HY-13636), a potent estrogen receptor inhibitor. Fulvestrant binds to and blocks the estrogen receptor, promotes its degradation, and thereby inhibits receptor dimerization, nucleocytoplasmic shuttling and transcriptional activity. Fulvestrant effectively blocks estrogen signaling, MAPK pathway activation and ER-regulated protein expression. Fulvestrant induces apoptosis, inhibits the proliferation of breast cancer and prolactinoma cells, and reduces the mineralization level, alkaline phosphatase activity and osteocalcin expression of preosteoblasts. Prenatal exposure to Fulvestrant impairs ovarian follicular development and causes ovarian structural damage. Fulvestrant has been widely used in studies related to breast cancer, prolactinoma and other conditions [3] .
Cat. No.: HY-146485S
Cat. No.: HY-176225
CAS No.: 3117131-00-4
Target:
Research Areas:
BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model .
Cat. No.: HY-187547
CAS No.: 2810801-22-8
PI3K-IN-64 is an orally effective phosphoinositide 3-kinase (PI3K) inhibitor. PI3K-IN-64 inhibits tumor growth in vivo. PI3K-IN-64 produces synergistic effects when combined with Fulvestrant (HY-13636) and Palbociclib (HY-50767). PI3K-IN-64 can be used for research on breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
